Dale Chappell

Title: Dale Chappell: Innovator in CAR-T Cell Therapy

Introduction

Dale Chappell is a notable inventor based in Dolores, Colorado. She has made significant contributions to the field of cancer treatment through her innovative work in chimeric antigen receptor (CAR) technology. Her research focuses on developing targeted therapies that can improve patient outcomes in solid tumor cancers.

Latest Patents

Dale Chappell holds a patent for "EphA3 directed CAR-T cells for treatment of tumors." This invention provides chimeric antigen receptors (CARs) that specifically target human EphA3. Additionally, it includes dual targeting CARs that bind to both human EphA3 and the human mutant epidermal growth factor receptor variant III (EGFRvIII). The patent also encompasses CAR-T cells that incorporate these CARs and methods for treating solid tumor cancers by administering the CARs.

Career Highlights

Chappell is affiliated with the Mayo Foundation for Medical Education and Research, where she continues to advance her research in CAR-T cell therapies. Her work is pivotal in the ongoing efforts to develop more effective cancer treatments.

Collaborations

Dale collaborates with esteemed colleagues, including Cameron Durrant and Saad J Kenderian, who contribute to her research initiatives and help drive innovation in the field.

Conclusion

Dale Chappell's contributions to CAR-T cell therapy exemplify the impact of innovative research in the medical field. Her patent for EphA3 directed CAR-T cells represents a significant advancement in cancer treatment, showcasing her dedication to improving patient care.